Fludarabine in chronic lymphocytic leukaemia (Q36548735)

14 August 2017

1 reference

title

Fludarabine in chronic lymphocytic leukaemia (English)

1 reference

14 August 2017

0 references

1 reference

2

Michael Hallek

1 reference

14 August 2017

Thomas Elter

1

1 reference

PubMed ID

16872267

14 August 2017

Andreas Engert

series ordinal

3

1 reference

PubMed ID

16872267

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

12

1 reference

14 August 2017

1641-1651

1 reference

Cellular and clinical pharmacology of fludarabine

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1641

10.1517/14656566.7.12.1641

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16872267